Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Genitourinary 1

Conditions

Prostatic Neoplasms 5Neoplasm Metastasis 2Prostate Carcinoma Metastatic to the Bone 1Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Castrate-Resistant Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Bone Metastatic Castration-resistant Prostate Cancer 1Bone Diseases 1

Interventions

pembrolizumab 59Gemcitabine 37Biopsy 33Specimen Handling 32Paclitaxel 30Magnetic Resonance Spectroscopy 30Nivolumab 29Cisplatin 26Carboplatin 25Irinotecan 24Cyclophosphamide 23Fluorouracil 22Bevacizumab 22Docetaxel 21Oxaliplatin 19Leucovorin 18Ipilimumab 17Cetuximab 17Capecitabine 17130-nm albumin-bound paclitaxel 16Everolimus 15Albumin-Bound Paclitaxel 15Trastuzumab 13olaparib 12Pemetrexed 12Erlotinib Hydrochloride 12spartalizumab 11Sorafenib 11Radiosurgery 11trastuzumab deruxtecan 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Neoplasm Metastasis × radium Ra 223 dichloride × Clear all
NCT01798108 2017-05-19

Dose Escalation Study of Radium-223 Dichloride in Patients With Advanced Skeletal Metastases

Bayer

Phase 1 Completed
31 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT00748046 2014-06-25

Alpharadinâ„¢ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton

Bayer

Phase 1 Completed
10 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡